A phase III randomized trial of cisplatin and paclitaxel administered by either 24 hour or 96 hour infusion in patients with selected stage III or stage IV epithelial ovarian cancer (GOG162)

Spriggs, David R.; Brady, Mark F.; Rubin, Stephen C.; Hanley, Michael; Clarke-Pearson, D.; Burger, Robert A.

doi:10.1200/jco.2004.22.90140.5004

Cited by 6 publications

(27 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Details regarding eligibility criteria, treatment, and outcome for each particular study have been previously published. [10][11][12][13][14][15][16] All patients provided written informed consent consistent with federal, state, and local requirements before receiving protocol therapy.…”

Section: Methodsmentioning

confidence: 99%

“…Both of these entities are rare in the advanced disease setting, together accounting for approximately 5% to 8% of all patients in clinical trials. [10][11][12][13][14][15][16][17][18] Unfortunately, survival of these patients has been shown to be poor. 17,18 There are also reports that these 2 histologies are relatively resistant to cytotoxic chemotherapy, [19][20][21][22] and that the CA-125 antigen may not be secreted in the mucinous cell type.…”

mentioning

confidence: 99%

“…To examine unique clinical features of advanced clear cell and mucinous epithelial ovarian cancers, with a particular focus on the predictive value of serum CA-125 antigen in these settings, a review was conducted of 7 Gynecologic Oncology Group (GOG) phase III clinical trials. [10][11][12][13][14][15][16] Reported here are the results of that evaluation.…”

mentioning

confidence: 99%

See 2 more Smart Citations

CA‐125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers

Tian

Markman

Zaino

et al. 2009

Cancer

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

CA‐125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers

Tian

Markman

Zaino

et al. 2009

Cancer

View full text Add to dashboard Cite

show abstract

“…The GOG 162 trial was a phase III randomized trial of cisplatin-paclitaxel administered either by 24or 96-h infusion in 293 patients with suboptimally debulked stage III or stage IV epithelial ovarian cancer. Prolonged paclitaxel infusion did not significantly increase the duration of survival over a 24-h infusion (9) . In addition, two other randomized trials evaluated different schedules of paclitaxel in recurrent disease.…”

Section: Modification Of Platinum-paclitaxelmentioning

confidence: 71%

Future options for first-line therapy of advanced ovarian cancer

Bois

Pfisterer

2005

Int J Gynecol Cancer

View full text Add to dashboard Cite

The current standard of treatment for patients with advanced ovarian cancer has been established in light of the results from various clinical trials. After debulking surgery, a combination of carboplatin and paclitaxel is considered to be the best treatment option in terms of survival and quality of life. However, since most patients on this chemotherapy modality will experience relapse, several studies have explored, and continue to do so, various modifications and alternatives to standard therapy in order to attain improved efficacy. Various modifications of dose, schedule, or route of standard regimens have shown no benefit, apart from intraperitoneal therapy, which has produced mixed results and would benefit from a definitive trial. Studies of maintenance/consolidation therapy have been mainly negative, although a small number of trials have produced enough positive data to prompt two new studies powered to detect survival benefits. Various phase II trials have investigated “targeted therapies,” but until now no positive results have been recorded. Translational studies are needed to identify patients who will benefit from such specific treatment strategies. The current most evaluated modification of standard therapy is the addition of a third non–cross-resistant drug to carboplatin and paclitaxel. Data for the addition of anthracyclines have either been negative (epirubicin) or not yet analyzed (pegylated liposomal doxorubicin), while evaluable data are shortly expected for the addition of topotecan. Data on the addition of gemcitabine are eagerly awaited from two phase III trials.

show abstract

“…The GOG 162 trial was a phase III randomized trial of cisplatin–paclitaxel administered either by 24‐ or 96‐h infusion in 293 patients with suboptimally debulked stage III or stage IV epithelial ovarian cancer. Prolonged paclitaxel infusion did not significantly increase the duration of survival over a 24‐h infusion ( 9 ) . In addition, two other randomized trials evaluated different schedules of paclitaxel in recurrent disease.…”

Section: Modification Of Platinum–paclitaxelmentioning

confidence: 99%

Future options for first-line therapy of advanced ovarian cancer

Bois¹,

Pfisterer²

2005

Int J Gynecol Cancer

View full text Add to dashboard Cite

The current standard of treatment for patients with advanced ovarian cancer has been established in light of the results from various clinical trials. After debulking surgery, a combination of carboplatin and paclitaxel is considered to be the best treatment option in terms of survival and quality of life. However, since most patients on this chemotherapy modality will experience relapse, several studies have explored, and continue to do so, various modifications and alternatives to standard therapy in order to attain improved efficacy. Various modifications of dose, schedule, or route of standard regimens have shown no benefit, apart from intraperitoneal therapy, which has produced mixed results and would benefit from a definitive trial. Studies of maintenance/consolidation therapy have been mainly negative, although a small number of trials have produced enough positive data to prompt two new studies powered to detect survival benefits. Various phase II trials have investigated "targeted therapies," but until now no positive results have been recorded. Translational studies are needed to identify patients who will benefit from such specific treatment strategies. The current most evaluated modification of standard therapy is the addition of a third non-cross-resistant drug to carboplatin and paclitaxel. Data for the addition of anthracyclines have either been negative (epirubicin) or not yet analyzed (pegylated liposomal doxorubicin), while evaluable data are shortly expected for the addition of topotecan. Data on the addition of gemcitabine are eagerly awaited from two phase III trials.

show abstract

A phase III randomized trial of cisplatin and paclitaxel administered by either 24 hour or 96 hour infusion in patients with selected stage III or stage IV epithelial ovarian cancer (GOG162)

Cited by 6 publications

References 0 publications

CA‐125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers

CA‐125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers

Future options for first-line therapy of advanced ovarian cancer

Future options for first-line therapy of advanced ovarian cancer

Contact Info

Product

Resources

About